FilingSEC EDGAR6-K
Tiziana Life Sciences Files for Orphan Drug Designation for MSA Treatment
· SEC accepted
StagePhase 2a
Filing content
Tiziana Life Sciences has submitted a request to the FDA for Orphan Drug Designation for its intranasal foralumab candidate for the treatment of Multiple System Atrophy.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…